Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal muscle glucose uptake in CML patients receiving nilotinib or imatinib
NL-OMON48288Active, not recruiting
- Sponsor
- Fysiologie
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of nilotinib and imatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Fysiologie. Primary endpoints: Area under the glucose disappearance curve after exercise and glucose bolus and Skeletal muscle [18F]FDG uptake on PET/CT. Started Feb 2020; status: active, not recruiting.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON48288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48288.